


ResistancePlus[®] MG

M. genitalium (Mgen) + macrolide resistance

Enabling Resistance Guided Therapy


Resistance Guided Therapy Increases Cure Rate¹



- Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.¹
- Detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.²
- Macrolide resistance testing is **recommended by International, British, and Australian guidelines** on Mgen infection.³⁻⁶

Resistance & *Mycoplasma genitalium*

- 🌀 *Mycoplasma genitalium* (Mgen) is a sexually transmitted infection causing nongonococcal urethritis (NGU) and cervicitis, and is associated with pelvic inflammatory disease (PID).¹
- 🌀 Prevalence of Mgen infections in the general population ranges from 1-3%, with an increased incidence in men with NGU (10-20%).^{6,7}
- 🌀 Mgen is more prevalent than gonorrhoea and presents clinically similar symptoms to chlamydia — leading to potential mistreatment and increased resistance.^{8,9}
- 🌀 Mgen is commonly detected in rectal samples, is often asymptomatic, and exhibits high rates of macrolide resistance.^{2,6,10}




“Although the subclinical nature of Mgen in the rectum questions its significance, the high prevalence seen at this site could be a potential source of onward urethral transmission. Future work should assess the need for appropriate screening and treatment of MG infection in MSM, particularly those with HIV infection and high-risk sexual behaviour.”¹⁰

ResistancePlus[®] MG

A flexible and cost effective solution for your laboratory


- A single well test, combining Mgen detection and macrolide resistance - a clear advantage compared with detection-only tests.
- Easily implemented into your existing workflow, with minimal disruption.
- Pack sizes to suit your laboratory throughput, minimising reagent wastage.
- Positive controls available as well as amplification control material to enable testing from pre-extracted samples.

Simple workflow with minimal disruption or resource requirements



Easy set up, Simple Analysis, Fast Results[†]

Implement the complete SpeedX solution and get from sample to answer faster.



90
min

Sample extraction
(Automated)

60
min

PCR setup (Manual)
*Automated set-up
protocols available

70
min

Amplification with
ResistancePlus[®] MG

10
min

Data interpretation
(Automated)

Test	Resistance Detection	Time of Sample to Answer [†]
<i>ResistancePlus[®] MG</i>	Yes	3 hours 10 minutes
Competitor D	Yes	7 hours 10 minutes
Competitor F	No	3 hours 30 minutes
Competitor S	No	4 hours

[†] Total time calculated using over-lapping workflow of manual and automated steps.

ResistancePlus[®] MG is a multiplex qPCR test for detection of Mgen and five azithromycin resistance markers, validated for a range of specimen types including anorectal swabs.¹¹ Powered by proprietary **PlexPCR**[®] technologies demonstrating improved multiplex performance compared with other probe-based tests.¹²

Single-well **PlexPCR**[®] Test

Channel	Target
1	<i>M. genitalium</i> (MgPa)
2	23S rRNA (A2058T, A2058C, A2058G, A2059C, A2059G)
3	Internal Control

Demonstrated clinical performance^{1,11}

	MG Detection	Resistance Markers
Sensitivity	98%	92.5%
Specificity	100%	100%

Validated with urine, multiple swabs (anal, rectal, cervical, endocervical, vaginal, urethral, pharyngeal) and extracts (using **PlexPCR**[®] Amplification Control).¹¹

SpeedX Analysis **ResistancePlus**[®] MG

The complete solution includes validated software for automated result calling and simple sample processing. Supporting rapid, routine diagnostics with quality control, searchable databases, audit-trail, and user traceability. High security and GDPR compliant with LIS compatibility.

ResistancePlus[®] MG Positive Control

One control covers all your needs — Mgen detection and 5 mutations conferring macrolide resistance.

Product	Compatible	Size	Cat#
ResistancePlus [®] MG*	LC480 II	100 reactions	20001L-01
		25 reactions	2000125
	ABI 7500/ 7500 Fast/Dx	100 reactions	2000201
		25 reactions	2000225
ResistancePlus [®] MG Positive Control	All platforms	100 reactions	2000301
		25 reactions	2000325
ResistancePlus [®] MG Positive Control	All platforms	10 reactions	95001
PlexPCR [®] Amplification Control	All platforms	400 reactions	90002

1. Read TRH, et al CID June 5 2018 doi.org/10.1093/cid/ciy477. 2. Couldwell DL, et al. Sex Transm Infect. 2018 Mar 22. pii: sextrans-2017-053480. doi: 10.1136. 3. Jensen, M Cusini, M Gomberg. 2016 European guideline on Mycoplasma genitalium infections. 4. Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. 5. Australian STI Management Guidelines – *Mycoplasma genitalium* 2018. 6. Soni et al. British Association for Sexual Health and HIV national guideline for the management of infection with *Mycoplasma genitalium* (2018) 7. Baumann L, et al. Sex Transm Infect 2018;94:255-262. 8. Manhart LE, et al. Am J Public Health. 2007;97(6):1118-25. 9. Bradshaw CS et al. J Infect Dis. 2017;216 (suppl_2):S412-S419. 10. Soni S. Sex Transm Infect. 2010 Feb;86(1):21-4. 11. **ResistancePlus**[®] MG Instructions for use 12. Tan LY et al, PLOS ONE. Published online 23 Jan 2017 *Not for sale in USA. **ResistancePlus**[®] MG kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR**[®], **ResistancePlus**[®] & **SpeedX**[®] are registered trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty. Ltd. products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Australia - **SpeedX** Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Suite G16, National Innovations Centre
4 Cornwallis Street, Eveleigh,
Sydney, NSW 2015 Australia

Europe - **SpeedX** Ltd.

+44 (0)333 577 5210

sales.uk@speedx.com.au

Kemp House
152 - 160 City Road
London, EC1V 2NX, United Kingdom